Kraig Biocraft Laboratories Activates First Wave of 2026 Production Program
Rhea-AI Summary
Kraig Biocraft Laboratories (OTCQB: KBLB) announced on Feb. 17, 2026 that it has activated the first wave of its 2026 production program and moved bio-material into incubation ahead of a planned March 2026 production run. The company says it has initiated a multi-ton spider silk scale-up and expanded its manufacturing pipeline to pursue sustained monthly metric-ton-level production.
The initiative is described as the first major deployment under the 2026 roadmap, focused on execution, quality control, supply chain stability, and downstream processing capacity.
Positive
- 2026 production program activated on Feb. 17, 2026
- Bio-materials moved to incubation for March 2026 production run
- Initiated multi-ton scale-up targeting monthly metric-ton-level output
Negative
- Forward-looking plan with no assurance results will occur as stated
- March 2026 run is the first major deployment, implying execution risk
ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced that its 2026 production plan has officially moved from strategy to execution.
The Company has now moved bio-material to incubation, getting a jumpstart on its March production plan and formally initiating its multi-ton spider silk scale-up initiative.
This milestone follows Kraig’s recently announced 2026 production schedule. This aggressive plan is set to achieve sustained monthly production of recombinant spider silk cocoons at unprecedented commercial volumes. With the release of the first wave of production materials now complete, Kraig Labs has activated its expanded manufacturing pipeline and commenced field-level implementation.
"This is the moment where planning becomes production," said Kim Thompson, Kraig Labs CEO and Founder. "Our 2026 roadmap was built around disciplined expansion, operational efficiency, and multi-ton output. Today, that roadmap is in motion. Bio-materials have recently been moved to incubation in preparation for the March production run."
The March production run represents the first major deployment under the Company's 2026 plan. The initiative is designed to drive consistent output at levels never before seen, while reinforcing quality control, supply chain stability, and downstream processing capacity.
By initiating this production cycle, Kraig Labs is delivering on its commitment, creating the world's first reliable, repeatable, and scalable commercial spider silk manufacturing. The Company's vertically integrated model enables rapid deployment of materials, controlled expansion of silkworm rearing operations, and alignment with future customer demand.
"Our focus is clear," Thompson continued. "Execution. Volume. Commercialization. Every production cycle strengthens our position as the global leader in recombinant spider silk."
Kraig Labs expects this March run to set the pace for subsequent production cycles throughout 2026, forming the foundation for sustained monthly metric-ton-level spider silk production.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about recent Kraig Labs advancements, please watch the Company's investor updates at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
Kraig Labs Technology is built on a scientifically engineered silkworm which incorporates key spider silk proteins to produce recombinant spider silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
FAQ
What did Kraig Biocraft Laboratories (KBLB) announce on Feb. 17, 2026 about production?
When is Kraig Labs' March 2026 production run and what will it do for KBLB?
What scale is Kraig Biocraft targeting with the 2026 scale-up for KBLB?
How did Kraig Labs describe its manufacturing readiness for the 2026 plan (KBLB)?
Does the Feb. 17, 2026 announcement include any guarantees about production results for KBLB?
Where can investors find updates and investor materials about Kraig Biocraft (KBLB)?
